{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:07:41Z","timestamp":1788883661333,"version":"build-2803163510"},"posted":{"date-parts":[[2026,9,8]]},"group-title":"In Review","reference-count":29,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,7,27]]},"abstract":"<title>Abstract<\/title>\n                <p>Purpose\n This study aimed to quantify the incidence rate of suspected clinically relevant bacterial infections, defined as the initiation of therapeutic antibiotics in the emergency department or during hospitalization, in a cohort of first-line MM patients. Events were contextualized with treatment data, antibiotic prophylaxis use, and confirmed pathogens.\nMethods\n We conducted a retrospective observational cohort study using electronic medical records to determine the incidence of therapeutic antibiotic initiation, characterize affected patients, and evaluate event-related risk factors.\nResults\n A total of 214 patients (216 patient-years of follow-up) were included. The event rate was 33.8 events per 100 patient-years, with a median time to event of 92 days. Pneumonia was the most frequent clinical presentation (43.8%). A bacterial pathogen was identified in 31.5% of events, and 63% occurred despite antibiotic prophylaxis. Events despite prophylaxis most frequently followed combination therapy or occurred during the neutropenic phase after stem cell transplantation. Notably, bacteria identified during prophylaxis were generally not susceptible to the prophylactic antibiotic. CD38 targeting therapy as part of first-line treatment was an independent predictive factor for initiation of therapeutic antibiotics.\nConclusion\n Therapeutic antibiotics are frequently initiated during first-line MM treatment, even in the presence of prophylactic strategies. CD38 targeting therapy is an independent predictive factor for therapeutic antibiotic use, highlighting the need for refined risk stratification and individualized infection prevention strategies.<\/p>","DOI":"10.21203\/rs.3.rs-10498974\/v1","type":"posted-content","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:24:43Z","timestamp":1788881083000},"source":"Crossref","is-referenced-by-count":0,"title":["Bacterial infections in Multiple Myeloma: Incidence, Causes, and the Impact of Prophylaxis in First-Line Therapy"],"prefix":"10.21203","author":[{"given":"Asma El","family":"Mokaddam","sequence":"first","affiliation":[{"name":"St. Antonius Ziekenhuis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inger","family":"Nijhof","sequence":"additional","affiliation":[{"name":"St. Antonius Ziekenhuis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saara","family":"Vainio","sequence":"additional","affiliation":[{"name":"St. Antonius Ziekenhuis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel van den","family":"Broek","sequence":"additional","affiliation":[{"name":"St. Antonius Ziekenhuis"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.ejca.2018.07.005","article-title":"Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018","volume":"103","author":"Ferlay J","year":"2018","unstructured":"Ferlay J, Colombet M, Soerjomataram I, et al. (2018) Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer 103: 356\u2013387. DOI: 10.1016\/j.ejca.2018.07.005","journal-title":"Eur J Cancer"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar SK","year":"2014","unstructured":"Kumar SK, Dispenzieri A, Lacy MQ, et al. (2014) Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 28: 1122\u20138. DOI: 10.1038\/leu.2013.313","journal-title":"Leukemia"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1186\/s12885-016-2645-y","article-title":"Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen","volume":"16","author":"Jung S-H","year":"2016","unstructured":"Jung S-H, Cho M-S, Kim HK, et al. (2016) Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen. BMC Cancer 16: 613. DOI: 10.1186\/s12885-016-2645-y","journal-title":"BMC Cancer"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1002\/ajh.24796","article-title":"Recognition of early mortality in multiple myeloma by a prediction matrix","volume":"92","author":"Terebelo H","year":"2017","unstructured":"Terebelo H, Srinivasan S, Narang M, et al. (2017) Recognition of early mortality in multiple myeloma by a prediction matrix. Am J Hematol 92: 915\u2013923. DOI: 10.1002\/ajh.24796","journal-title":"Am J Hematol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/ejh.13264","article-title":"Understanding mortality in multiple myeloma: Findings of a European retrospective chart review","volume":"103","author":"Mohty M","year":"2019","unstructured":"Mohty M, Cavo M, Fink L, et al. (2019) Understanding mortality in multiple myeloma: Findings of a European retrospective chart review. Eur J Haematol 103: 107\u2013115. DOI: 10.1111\/ejh.13264","journal-title":"Eur J Haematol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"107365","DOI":"10.1016\/j.leukres.2023.107365","article-title":"Management of humoral secondary immunodeficiency in hematological malignancies and following hematopoietic stem cell transplantation: Regional perspectives","volume":"133","author":"Ar MC","year":"2023","unstructured":"Ar MC, El Fakih R, Gabbassova S, et al. (2023) Management of humoral secondary immunodeficiency in hematological malignancies and following hematopoietic stem cell transplantation: Regional perspectives. Leuk Res 133: 107365 DOI: 10.1016\/j.leukres.2023.107365.","journal-title":"Leuk Res"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3389\/fimmu.2019.00033","article-title":"The Expanding Field of Secondary Antibody Deficiency: Causes, Diagnosis, and Management","volume":"10","author":"Patel SY","year":"2019","unstructured":"Patel SY, Carbone J, Jolles S. (2019) The Expanding Field of Secondary Antibody Deficiency: Causes, Diagnosis, and Management. Front Immunol 10: 33 DOI: 10.3389\/fimmu.2019.00033.","journal-title":"Front Immunol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3324\/haematol.2024.285645","article-title":"Risk of infections in multiple myeloma. A populationbased study on 8,672 multiple myeloma patients diagnosed 2008\u20132021 from the Swedish Myeloma Registry","volume":"110","author":"Blimark CH","year":"2025","unstructured":"Blimark CH, Carlson K, Day C, et al. (2025) Risk of infections in multiple myeloma. A populationbased study on 8,672 multiple myeloma patients diagnosed 2008\u20132021 from the Swedish Myeloma Registry. Haematologica 110: 163\u2013172. DOI: 10.3324\/haematol.2024.285645","journal-title":"Haematologica"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","article-title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group","volume":"9","author":"Raje NS","year":"2022","unstructured":"Raje NS, Anaissie E, Kumar SK, et al. (2022) Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol 9: e143\u2013e161. DOI: 10.1016\/S2352-3026(21)00283-0","journal-title":"Lancet Haematol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/S1470-2045(19)30506-6","article-title":"Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial","volume":"20","author":"Drayson MT","year":"2019","unstructured":"Drayson MT, Bowcock S, Planche T, et al. (2019) Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. Lancet Oncol 20: 1760\u20131772. DOI: 10.1016\/S1470-2045(19)30506-6","journal-title":"Lancet Oncol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn M","year":"2009","unstructured":"Tomblyn M, Chiller T, Einsele H, et al. (2009) Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 15: 1143\u2013238. DOI: 10.1016\/j.bbmt.2009.06.019)","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref12","unstructured":"National Cancer Institute. (2017). Common Terminology Criteria for Adverse Events (CTCAE) v5.0. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm (2017, accessed 21 October 2024"},{"key":"ref13","unstructured":"Regionala cancercentrum. (2025). Nationellt v\u00e5rdprogram myelom. Version 3.3. https:\/\/kunskapsbanken.cancercentrum.se\/diagnoser\/myelom\/vardprogram\/ (2025, accessed 10 April 2025)"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1086\/605664","article-title":"Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents","volume":"49","author":"Nucci M","year":"2009","unstructured":"Nucci M, Anaissie E. (2009) Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis 49: 1211\u201325. DOI: 10.1086\/605664","journal-title":"Clin Infect Dis"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s12879-016-1648-2","article-title":"Epidemiology of invasive pneumococcal infections: manifestations, incidence and case fatality rate correlated to age, gender and risk factors","volume":"16","author":"Backhaus E","year":"2016","unstructured":"Backhaus E, Berg S, Andersson R, et al. (2016) Epidemiology of invasive pneumococcal infections: manifestations, incidence and case fatality rate correlated to age, gender and risk factors. BMC Infect Dis 16: 367. DOI: 10.1186\/s12879-016-1648-2","journal-title":"BMC Infect Dis"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1186\/s12879-020-05412-w","article-title":"Assessment of infection in newly diagnosed multiple myeloma patients: risk factors and main characteristics","volume":"20","author":"Lin C","year":"2020","unstructured":"Lin C, Shen H, Zhou S, et al. (2020) Assessment of infection in newly diagnosed multiple myeloma patients: risk factors and main characteristics. BMC Infect Dis 20: 699. DOI: 10.1186\/s12879-020-05412-w","journal-title":"BMC Infect Dis"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/bjh.13532","article-title":"Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy","volume":"171","author":"Teh BW","year":"2015","unstructured":"Teh BW, Harrison SJ, Worth LJ, et al. (2015) Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy. Br J Haematol 171: 100\u20138. DOI: 10.1111\/bjh.13532","journal-title":"Br J Haematol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.3390\/cancers13143439","article-title":"Antibiotic Prophylaxis or Granulocyte-Colony Stimulating Factor Support in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation","volume":"13","author":"Klein E-M","year":"2021","unstructured":"Klein E-M, Sauer S, Klein S, et al. (2021) Antibiotic Prophylaxis or Granulocyte-Colony Stimulating Factor Support in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation. Cancers (Basel) 13: 3439. DOI: 10.3390\/cancers13143439","journal-title":"Cancers (Basel)"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1038\/leu.2012.124","article-title":"Oral antibiotic prophylaxis of early infection in multiple myeloma: a URCC\/ECOG randomized phase III study","volume":"26","author":"Vesole DH","year":"2012","unstructured":"Vesole DH, Oken MM, Heckler C, et al. (2012) Oral antibiotic prophylaxis of early infection in multiple myeloma: a URCC\/ECOG randomized phase III study. Leukemia 26: 2517\u201320. DOI: 10.1038\/leu.2012.124","journal-title":"Leukemia"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/s0002-9343(95)00043-7","article-title":"Prophylactic antibiotics for the prevention of early infection in multiple myeloma","volume":"100","author":"Oken MM","year":"1996","unstructured":"Oken MM, Pomeroy C, Weisdorf D, et al. (1996) Prophylactic antibiotics for the prevention of early infection in multiple myeloma. Am J Med 100: 624\u20138. DOI: 10.1016\/s0002-9343(95)00043-7","journal-title":"Am J Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1093\/ofid\/ofac574","article-title":"Cumulative Incidence and Relative Risk of Infection in Patients With Multiple Myeloma Treated With Anti-CD38 Monoclonal Antibody-Based Regimens: A Systematic Review and Meta-analysis","volume":"9","author":"Vassilopoulos S","year":"2022","unstructured":"Vassilopoulos S, Vassilopoulos A, Kalligeros M, et al. (2022) Cumulative Incidence and Relative Risk of Infection in Patients With Multiple Myeloma Treated With Anti-CD38 Monoclonal Antibody-Based Regimens: A Systematic Review and Meta-analysis. Open forum Infect Dis 9: 574. DOI: 10.1093\/ofid\/ofac574","journal-title":"Open forum Infect Dis"},{"key":"ref22","author":"Johnsrud A","year":"2017","unstructured":"Johnsrud A, Susanibar S, Jo KJ, et al. (2017) Infectious Complications of Daratumumab-Containing Therapy for Multiple Myeloma. Blood; 130, https:\/\/ashpublications.org\/blood\/article-split\/130\/Supplement 1\/3148\/80806\/Infectious-Complications-of-Daratumumab-Containing."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"e0211927","DOI":"10.1371\/journal.pone.0211927","article-title":"Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma","volume":"14","author":"Nahi H","year":"2019","unstructured":"Nahi H, Chrobok M, Gran C, et al. (2019) Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma. PLoS One 14: e0211927. DOI: 10.1371\/journal.pone.0211927","journal-title":"PLoS One"},{"key":"ref24","unstructured":"Janssen-Cilag International. Darzalex (daratumumab), Summary Of Product Characteristics, https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/darzalex (2025, accessed 10 April 2025)."},{"key":"ref25","author":"Hong J","year":"2024","unstructured":"Hong J, Zhou B, Pak A, et al. (2024) Hypogammaglobulinemia and Risk of Infection Following Daratumumab in Patients with Multiple Myeloma. J Allergy Clin Immunol: 2 Supplement 153."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.1182\/blood-2019-127247","article-title":"Hypogammaglobulinemia and Its Implications in Patients Treated with Daratumumab: A Single Institution Experience","volume":"134","author":"Paul Y","year":"2019","unstructured":"Paul Y, Aguirre LE, Basher F, et al. (2019) Hypogammaglobulinemia and Its Implications in Patients Treated with Daratumumab: A Single Institution Experience. Blood 134: 3131\u20133131. DOI: 10.1182\/blood-2019-127247","journal-title":"Blood"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/ejh.13190","article-title":"Risk factors for infections in newly diagnosed Multiple Myeloma patients: A Danish retrospective nationwide cohort study","volume":"102","author":"S\u00f8rrig R","year":"2019","unstructured":"S\u00f8rrig R, Klausen TW, Salomo M, et al. (2019) Risk factors for infections in newly diagnosed Multiple Myeloma patients: A Danish retrospective nationwide cohort study. Eur J Haematol 102: 182\u2013190. DOI: 10.1111\/ejh.13190","journal-title":"Eur J Haematol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1086\/313896","article-title":"Fever in the elderly","volume":"10","author":"Norman DC","year":"1996","unstructured":"Norman DC, Yoshikawa TT. (1996) Fever in the elderly. Infect Dis Clin North Am 10: 93\u20139. DOI: 10.1086\/313896","journal-title":"Infect Dis Clin North Am"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.7150\/jca.24288","article-title":"Multiple Myeloma Index for Risk of Infection","volume":"9","author":"Valkovic T","year":"2018","unstructured":"Valkovic T, Gacic V, Nacinovic-Duletic A. (2018) Multiple Myeloma Index for Risk of Infection. J Cancer 9: 2211\u20132214. DOI: 10.7150\/jca.24288","journal-title":"J Cancer"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-10498974\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-10498974\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:24:46Z","timestamp":1788881086000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-10498974\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":29,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-10498974\/v1","relation":{},"subject":[],"published":{"date-parts":[[2026,9,8]]},"subtype":"preprint"}}